Direct-Acting Antiviral (DAA) Agents Used to Treat Chronic Hepatitis C Virus (HCV) Medication Therapy Worksheet for Louisiana Medicaid Recipients

Note: This worksheet must be completed in full and submitted with supporting documentation where applicable. [See DAA Clinical Authorization Criteria]

Recipient Name:	cipient Name: Medicaid Recipient ID #:				Recipient DOB:		Recipient weight:
Prescriber Name: Prescriber Specialty:			Medicaid Provide	Provider ID #: Office (ce Contact:	
Medication regimen requested [Choose one.]							
☐ Daclatasvir (Daklinza [™]) ☐ Daclatasvir / Sofosbuvir (Daklinza [™] / Sovaldi®)							
☐ Elbasvir / Grazoprevir (Zepatier®)				Glecaprevir / Pibrentasvir (Mavyret™)			
☐ Ledipasvir / Sofosbuvir (Harvoni®)				Ombitasvir / Paritaprevir / Ritonavir with Dasabuvir (Viekira Pak™)			
☐ Ledipasvir / Sofosbuvir (Authorized Generic (AG) of Harvoni®) ☐				Sofosbuvir / Velpatasvir (Epclusa®)			
☐ Sofosbuvir (Sovaldi®) ☐				Sofosbuvir / Velpatasvir / Voxilaprevir (Vosevi TM)			
Sofosbuvir / Velpatasvir (Authorized Generic (AG) of Epclusa®) [This form is not necessary because Epclusa® AG is preferred and does not require authorization.]							
Duration of therapy requested:weeks [If duration is greater than minimum duration stated per prescribing information, please provide rationale below for extended duration.]							
Reason for extended duration request (if applicable):							
Does patient have a diagnosis of Chronic Hepatitis C (HCV)? Yes No Please specify genotype:							
Is patient treatment-naïve? ☐ Yes ☐ No If no, provide previous HCV therapy:							
Was previous therapy completed? Yes No If no, provide reason for discontinuation.							
Has the patient experienced treatment failure with the preferred product? Yes No							
Has the patient had an intolerable side effect with the preferred product?							
If yes, please explain in detail:							
Does the patient have documented contraindication(s) to the preferred product? Yes No							
If yes, please explain in detail:							
If there is no preferred product that is appropriate to use for the condition being treated, please explain in detail:							
1 Francisco de la companya del companya de la companya del companya de la company							
By signing below, the prescriber attests that the information provided herein is true and accurate to the best of his/her knowledge. Also, by signing and submitting this request form, the prescriber attests to statements in the 'Attestation' section of the criteria specific to this request.							
- equesor							
Physician Signature:*						Date:	
	*(Signature star	nps and proxy signatures are not a	accept	able.)			

CONFIDENTIAL NOTICE

The documents accompanying this facsimile transmission may contain confidential information which is legally privileged. The information is intended only for the use of the individual or entity to which it is addressed. If you are not the intended recipient you are hereby notified that any review, disclosure/re-disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy this information.